Navigation Links
Cardiogenesis Reports First Quarter 2009 Results
Date:5/14/2009

tatements. Any forward-looking statements in this news release are subject to numerous risks and uncertainties, many of which are outside the Company's control, that could cause actual results to differ materially. Factors that could affect the accuracy of these forward-looking statements include, but are not limited to: any inability by the Company to sustain profitable operations or obtain additional financing on favorable terms if and when needed; any failure to obtain required regulatory approvals; failure of the medical community to expand its acceptance of TMR procedures; possible adverse governmental rulings or regulations, including any FDA regulations or rulings; the Company's ability to comply with international and domestic regulatory requirements; possible adverse Medicare or other third-party reimbursement policies or adverse changes in those policies; any inability by the Company to ship product on a timely basis; the Company's ability to manage its growth; the effects of recent disruptions in global credit and equity markets and other adverse economic developments that could adversely affect the market for our products or our ability to raise needed financing; actions by our competitors; and the Company's ability to protect its intellectual property. Other factors that could cause Cardiogenesis' actual results to differ materially are discussed in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and the Company's other filings with the Securities and Exchange Commission. The Company disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

                             CARDIOGENESIS CORPORATION
                   CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                       (in thousands, except per share amounts)
                                    (una
'/>"/>
SOURCE Cardiogenesis Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Cardiogenesis Reports Fourth Quarter and Fiscal Year 2008 Results
2. Cardiogenesis Corporation to Report 2008 Fourth Quarter and Year-End Results on March 31st
3. Cardiogenesis Announces Successful Educational Symposium at Society of Thoracic Surgeons Meeting in San Francisco
4. Cardiogenesis Corporation to Report Third Quarter 2008 Results on November 13th
5. Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C.
6. Cardiogenesis Announces Preliminary Results Combining TMR + Platelet Rich Plasma (PRP)
7. Cardiogenesis Reports First Quarter 2008 Results
8. Cardiogenesis Corporation to Report 2008 First Quarter Results on May 15th
9. Cardiogenesis Corporation Announces Rescheduled Fourth Quarter and Full Year 2007 Earnings Release
10. Cardiogenesis Corporation Reports Delay in Earnings Release and Conference Call
11. Cardiogenesis Corporation to Report 2007 Fourth Quarter and Year-End Results on March 4th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... 17, 2014 Giving patients adrenaline after they suffer a ... their prospects of surviving long-term, according to new research ... of patients who have a cardiac arrest get adrenaline, ... arrest for decades," said Dr. Steve Lin, an emergency ... despite advances in medical treatment, long-term survival rates of ...
(Date:4/17/2014)... the leading weapon against the deadly disease could be ... indicating it simply needs to be administered differently. , ... anti-malarial drug chloroquine in treating and preventing the mosquito-bourne ... a million people each year around the world. , ... chloroquine, but research carried out at the Australian National ...
(Date:4/16/2014)... Calif. Consider the marvel of the embryo. It begins ... function as they multiply to become the cells of our ... the body. , Now, in a feat of reverse tissue ... genetic coding that allows embryonic cells to proliferate and transform ...
(Date:4/16/2014)... Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today that ... in solid tumors, including long-term patient follow-up, have been ... Issue 232). The data demonstrate robust antibody and T ... with very advanced cancers and suggest that CDX-1401 may ...
(Date:4/16/2014)... 16, 2014 According to a new study, endoscopists, ... with one to two small polyps are consistent with ... may be an appropriate target for quality indicators. This ... adherence to guidelines for timing of repeat colonoscopy after ...
Breaking Medicine News(10 mins):Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2Health News:Scientists find new way to fight malaria drug resistance 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 3
... workers 85 percent rate workplace safety first in ... leave, minimum wage, paid sick days, overtime pay and the ... from the National Opinion Research Center at the University of ... with Workplace Safety," draws on dozens of surveys and polls ...
... HealthDay Reporter , MONDAY, Aug. 30 (HealthDay News) ... in patients with nerve pain stemming from injuries or ... chronic nerve pain were taught to take a single ... three times a day, for five days. The cannabis ...
... Specifically asking young women during visits to family planning ... to become pregnant a type of intimate-partner violence ... the women would continue to experience such pressures, according ... the UC Davis School of Medicine. Young women ...
... , This release is available in French ... debated by clinicians, researchers, legislators and the public at large ... for pain, which may not always be effective and may ... Health Centre (MUHC) and McGill University researchers provides evidence that ...
... It may soon be possible to identify patients who ... the blood specific to the disease. These findings are ... issue of Nature and conducted by doctors ... techniques to understand infections. Tuberculosis (TB) is ...
... News) -- While the hormone oxytocin makes people more trusting, ... Oxytocin -- a naturally occurring hormone that functions as ... role in social behavior. Increased levels of the hormone have ... generosity and trust, but it hasn,t been known whether this ...
Cached Medicine News:Health News:Workers rate safety most important workplace issue in new Labor Day study 2Health News:Smoked Marijuana May Ease Chronic Nerve Pain 2Health News:Smoked Marijuana May Ease Chronic Nerve Pain 3Health News:Study finds asking about pregnancy coercion and intimate-partner violence can reduce their incidence 2Health News:Study finds asking about pregnancy coercion and intimate-partner violence can reduce their incidence 3Health News:Research demonstrates benefits of medical cannabis as a treatment for chronic pain 2Health News:New genomic marker for tuberculosis may help identify patients who will develop the disease 2Health News:New genomic marker for tuberculosis may help identify patients who will develop the disease 3Health News:Oxytocin Increases Trust, Not Gullibility 2
(Date:1/15/2014)... Jan. 15, 2014 The Cadence Fitness & Health ... by the Medical Fitness Association, a non-profit organization assisting ... full potential. The Cadence Fitness & Health Center is ... and second in the Chicagoland area. "The ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Advanced Drug Delivery Systems -- Focus on ... STUDY OBJECTIVES A ...
(Date:1/14/2014)...  Luminex Corporation (Nasdaq: LMNX ) today announced that ... 2013 on Monday, February 3, 2014. A press release announcing ... trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... highlights and financial results for the fourth quarter and twelve ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... 23 Neurobiological Technologies, Inc. (Nasdaq: NTII ) ("NTI") ... extraordinary dividend of $0.18 per share of common stock, which ... record as of November 30, 2009. The December 9, 2009 ... pursuant to a plan of complete liquidation and dissolution and ...
... Calif., Nov. 23 Advanced Sterilization Products (ASP), ... today the acquisition by its French affiliate, Apsis ... of innovative disinfection processes and technologies to prevent ... disclosed. , Gloster Europe designs and markets ...
Cached Medicine Technology:Neurobiological Technologies Announces Extraordinary Dividend of $0.18 per Share 2ASP Announces Acquisition of Gloster Europe to Help Reduce Infections in Healthcare Facilities 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: